Skip to main content

Advertisement

SpringerLink
Log in

Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

MicroRNA (miRNA) expression is deregulated in many types of human cancers, including thyroid cancer. The purpose of this study was to investigate miRNA deregulation in papillary thyroid carcinoma (PTC), particularly with lymph node (LN) metastasis. To identify the miRNA signature in PTC with LN metastasis, miRNAs isolated from PTC patients with LN metastasis (n = 3) and without LN (NLN) metastasis (n = 3) were used for microarray analysis. Four differentially expressed miRNAs including miR-2861, miR-451, miR-193b, and miR-1202 were selected for further validation between the LN group (n = 51) and the NLN group (n = 36) using real-time quantitative reverse transcription–polymerase chain reaction (qRT-PCR). The miRNA microarray results showed that compared to the NLN group, upregulation of four miRNAs including miR-2861, miR-451, miR-193b, and miR-1202 was associated with LN metastasis, whereas four other miRNAs including miR-let-7i, miR-542-5p, miR-664*, and miR-564 were downregulated in the LN group. In the validation cohort, the expression of either miR-2861 or miR-451 in the LN group was significantly greater than that in the NLN group (P = 0.004 and 0.026, respectively). Furthermore, the expression levels of miR-2861 and miR-451 in lateral lymph node (LLN) metastasis were significantly greater than those in central lymph node (CLN) metastasis (P = 0.007 and 0.001, respectively). Upregulated expression of miR-2861 and miR-451 in PTC with LN metastasis represents a unique miRNA signature associated with the prognosis and progression of PTC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, et al. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg. 2007;31(11):2085–91.

    Article  PubMed  Google Scholar 

  2. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742–62.

    Article  PubMed  CAS  Google Scholar 

  3. Lim YS, Lee JC, Lee YS, Lee BJ, Wang SG, Son SM, et al. Lateral cervical lymph node metastases from papillary thyroid carcinoma: predictive factors of nodal metastasis. Surgery. 2011;150(1):116–21.

    Article  PubMed  Google Scholar 

  4. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA. 2004;101(32):11755–60.

    Article  PubMed  CAS  Google Scholar 

  5. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA pre-cursors in human cell lines. Nucleic Acids Res. 2005;33(17):5394–403.

    Article  PubMed  CAS  Google Scholar 

  6. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8.

    Article  PubMed  CAS  Google Scholar 

  7. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103(7):2257–61.

    Article  PubMed  CAS  Google Scholar 

  8. Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee YF, et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF (V600E) mutation. Thyroid. 2010;20(5):489–94.

    Article  PubMed  CAS  Google Scholar 

  9. Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE, et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011;18(7):2035–41.

    Article  PubMed  Google Scholar 

  10. Zhou YL, Liu C, Dai XX, Zhang XH, Wang OC. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas. Med Oncol. 2012;29(5):3360–6.

    Article  PubMed  CAS  Google Scholar 

  11. Chou CK, Yang KD, Chou FF, Huang CC, Lan YW, Lee YF, et al. Prognostic implications of miR-146b expression and Its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2013;98(2):E196–205.

    Article  PubMed  CAS  Google Scholar 

  12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods. 2001;25(4):402–8.

    Article  PubMed  CAS  Google Scholar 

  13. Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H, et al. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer. 2012;106(4):740–7.

    Article  PubMed  CAS  Google Scholar 

  14. Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, et al. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol. 2011;17(35):3976–85.

    Article  PubMed  CAS  Google Scholar 

  15. Nan Y, Han L, Zhang A, Wang G, Jia Z, Yang Y, et al. MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res. 2010;1359:14–21.

    Article  PubMed  CAS  Google Scholar 

  16. Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, et al. Expression of microRNAs in basal cell carcinoma. Br J Dermatol. 2012;167(4):847–55.

    Article  PubMed  CAS  Google Scholar 

  17. Gimm O, Rath FW, Dralle H. Pattern of lymph node metastases in papillary thyroid carcinoma. Br J Surg. 1998;85(2):252–4.

    Article  PubMed  CAS  Google Scholar 

  18. Fabbri M, Ivan M, Cimmino A, Negrini M, Calin GA. Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther. 2007;7(7):1009–19.

    Article  PubMed  CAS  Google Scholar 

  19. Kitano M, Rahbari R, Patterson EE, Steinberg SM, Prasad NB, Wang Y, et al. Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. Thyroid. 2012;22(3):285–91.

    Article  PubMed  CAS  Google Scholar 

  20. Shen R, Liyanarachchi S, Li W, Wakely PE Jr, Saji M, Huang J, et al. MicroRNA signature in thyroid fine needle aspiration cytology applied to “atypia of undetermined significance” cases. Thyroid. 2012;22(1):9–16.

    Article  PubMed  CAS  Google Scholar 

  21. Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res. 2012;18(7):2032–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported by the Innovation Team Project of Education Department of Liaoning Province (No: LT2010102) and the Liaoning Baiqianwan Talents Program (No: 2010921070). We thank Medjaden Bioscience Limited for assisting in the preparation of this manuscript.

Conflict of interest

The authors declare no conflict of interests exist in relation to the publication of this study. We have full control of all primary data and we agree to allow the journal to review our data if needed.

Ethical standard

Our study protocol was approved by the Ethics Committee of the First Affiliated Hospital of China Medical University, Shenyang, China. Written informed consent was obtained from all study participants.

Author information

Authors and Affiliations

  1. Department of General Surgery, The First Hospital of China Medical University, No. 155, Nanjing Bei Street, Heping District, Shenyang, 110001, Liaoning Province, People’s Republic of China

    Zhihong Wang, Hao Zhang & Ping Zhang

  2. Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, Shenyang, 110001, People’s Republic of China

    Jing Li, Zhongyan Shan & Weiping Teng

Authors
  1. Zhihong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhongyan Shan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weiping Teng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hao Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, Z., Zhang, H., Zhang, P. et al. Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis. Med Oncol 30, 577 (2013). https://doi.org/10.1007/s12032-013-0577-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0577-9

Keywords

Search

Navigation